Todd C. DAVIS

Previously, Mr. Davis served as a partner responsible for biopharmaceutical growth equity investments at Apax Partners.

Mr. Davis began his business career in sales at Abbott Laboratories where he held several sales and marketing positions of increasing responsibility. Subsequently he led corporate development and held strategic planning and general management responsibilities at Elan Pharmaceuticals. Cumulatively he has almost thirty years of experience in both operations and investing in the biopharmaceutical and life sciences industries.

Mr. Davis has been involved in over $3 billion of healthcare financings including growth equity, public equity turnarounds, structured debt and royalty acquisitions. He has also led, structured and closed over 40 additional intellectual property licenses, as well as hybrid royalty-debt transactions.

Mr. Davis is a navy combat veteran and holds a B.S. from the U.S. Naval Academy and an M.B.A. from Harvard University.

He currently serves on the boards of Ligand Pharmaceuticals, Palvella Therapeutics Inc. and ViroCell Biologics. He is a former board member of the Harvard Business School Healthcare Alumni Association.